1249 GMT - Novo Nordisk has had a constructive first quarter on many fronts, but Barclays lowers its forecasts heading into the earnings report on lower Wegovy and Ozempic volumes in the U.S. than it previously forecast. Novo Nordisk has come off the FDA drugs shortage list and introduced its NovoCare direct-to-patient pharmacy efforts. But prescriptions didn't grow to the extent the bank needed them to in order to meet its forecasts. The bank now expects group sales growth this year at 19% at constant exchange rates, below the midpoint of company guidance at 16%-24%. A guidance cut at the first-quarter earnings report is "certainly possible, although Barclays continues to believe in the long-term story. Shares fall 2.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 31, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。